Trading at $6 even. The expansion of the sgi-110 trial will included Relaspe/refractory mds and aml pts. Vidaza and dacogen never attempted this. This drugs not afraid of anything. Give me the worst, I will show improvements. You got to like a drug with #$%$!
Winner Winner chicken dinner. Free, the RBC report has a value of $4 per share on value on SGI-110 as a "base case". $2 on Dacogen Royalty and $3 for the pipeline. That gives them their price target of $9. Thinking that $4 for SGI-110 is low considering potential for this monster drug.